Skip to main content

Day: August 9, 2022

With Worldwide Revenues (Excluding Pre-Paid Cards) in Q2 2022 Increasing 32% Year-over-Year, Ebix Announces Q2 2022 Results

Q2 Revenues of $250.8 million, with 2% Year-over-Year (YOY) Growth Q2 Diluted EPS of $0.63, with 23% YOY Growth Q2 GAAP Operating Income of $30.1 million, with 10% YOY Growth Q2 Operating Cash flow of $21.4 millionJOHNS CREEK, Ga., Aug. 09, 2022 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of on-demand software and e-commerce services to the insurance, financial services, travel, healthcare, and e-learning industries today announced the following results for the quarter ended June 30, 2022:Revenues of $250.8 million GAAP operating income of $30.1 million and Non-GAAP operating income of $34.0 million GAAP Diluted EPS of $0.63 and Non-GAAP diluted EPS of $0.75.Ebix will host a conference call to review its results today at 11:00 a.m. EDT (details below). Robin Raina, President & CEO,...

Continue reading

SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2022

Steady Operational Performance Amidst Macroeconomic Headwinds BOSTON and LAUSANNE, Switzerland, Aug. 09, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsRevenue for the second quarter of 2022 was $11.7 million, representing year-over-year growth of 15%; constant currency revenue growth excluding COVID-19-related revenues was 36% Gross margin was 65% for the second quarter of 2022 compared to 61% for the second quarter of 2021; adjusted gross margin was a record 67% for the second quarter of 2022 compared to 62% for the second quarter of 2021 Fiscal year 2022 constant currency revenue growth guidance range maintained at 30% to 35%; reported revenue guidance updated to...

Continue reading

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

– CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 – – Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program – – Management to Host Webcast and Conference Call Today at 8:30 A.M. ET – ALPHARETTA, Ga., Aug. 09, 2022 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “We are building significant momentum through our internal and partnered programs leveraging our proprietary SCS platform technology,” said George Lasezkay, Pharm.D., J.D., Clearside’s President...

Continue reading

With 21.4% CAGR, Surgical Robots Market Size worth USD 6,875.1 Million in 2026

According to Fortune Business Insights, Global Surgical Robots Market size stood at USD 1,463.0 million in 2018 and is projected to reach USD 6,875.1 million by 2026, exhibiting a CAGR of 21.4% between 2018 and 2026. Minimally Invasive Robot-sssisted Surgeries Will Favor Market Growth Pune, India, Aug. 09, 2022 (GLOBE NEWSWIRE) — The global surgical robots market will derive growth from recent technological advancements that have enabled minimally invasive surgeries. According to a report published by Fortune Business Insights, titled “Surgical Robots: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 1,463.0 Mn in 2018. Fortune Business Insights predicts that the market will reach 6,875.1 Mn by 2026, thereby exhibiting a CAGR of 21.4% during the forecast period. Surgical robots are used to...

Continue reading

With 5.0% CAGR, Orthopedic Implants Market Size worth USD 60.90 Billion by 2029

According to Fortune Business Insights, the global Orthopedic Implants Market size is projected to reach USD 60.90 Billion by 2029, at CAGR of 5.0% during forecast period; Increase in Geriatric Population and Rise in Orthopedic Diseases Will Boost the Market Growth Pune, India, Aug. 09, 2022 (GLOBE NEWSWIRE) — The global orthopedic implants market size hit USD 41.20 billion in 2021. The market value is slated to rise from USD 43.14 billion in 2022 to USD 60.90 in 2029, exhibiting a CAGR of 5.0% during the forecast period. Orthopedic implants are devices used to replace or support a damaged bone designed with metallic alloys, such as stainless steel and titanium, says Fortune Business InsightsTM in its report titled, “Orthopedic Implants Market, 2022-2029”.Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/orthopedic-implants-market-101659Key...

Continue reading

Cryptocurrency Market Worth USD 1902.5 Billion in 2028 | Exhibiting a CAGR of 47.6% [2021-2028]

According to Fortune Business Insights, the global cryptocurrency market size is projected to reach USD 1902.5 billion in 2028, at a CAGR of 11.1% during the forecast period, 2021-2028 Pune, India, Aug. 09, 2022 (GLOBE NEWSWIRE) — The global cryptocurrency market is projected to rise from USD 910.3 million in 2021 to USD 1902.5 million by 2028 at a CAGR  of 11.1% during the forecast period. Fortune Business Insights™ has delved into these insights in its latest research report titled, “Cryptocurrency Market Forecast, 2021-2028.” As per the report, the global market size stood at USD 826.6 million in 2020. Key Industry Development: March 2021 – Visa Inc. aims to introduce crypto as a direct payment. With this key initiative, the company aims to accept cryptocurrencies as a payment method for the finance industry.Get Sample PDF...

Continue reading

With 15.0% CAGR, Self-Checkout Systems Market Worth USD 12.01 Billion by 2029

According to Fortune Business Insights, Self-Checkout Systems Market size is projected to reach USD 12.01 billion in 2029, at a CAGR of 15% during the forecast period Pune, India, Aug. 09, 2022 (GLOBE NEWSWIRE) — The global self-checkout systems market size was valued at USD 3.90 billion in 2021. The market is projected to grow from USD 4.51 billion in 2022 to USD 12.01 billion by 2029, exhibiting a CAGR of 15.0% during the forecast period. This information is provided by Fortune Business Insights, in its report, titled, “Self-Checkout Systems Market, 2022-2029.” The bolstering demand for automation and cloud-based Self-Checkouts (SCO) in the retail sector for price as well as time proficiency fuels the market for self-checkout systems. Moreover, multiple pioneering players in the market are embracing these advanced solutions in...

Continue reading

Devon Energy Announces Bolt-On Acquisition in the Eagle Ford

OKLAHOMA CITY, Aug. 09, 2022 (GLOBE NEWSWIRE) — Devon Energy Corp. (NYSE: DVN) announced today it has entered into a definitive purchase agreement to acquire Validus Energy, an Eagle Ford operator, for total cash consideration of $1.8 billion. The transaction is subject to customary terms and conditions and is expected to close at the end of the third quarter of 2022, with an effective date of June 1, 2022. Rick Muncrief, president and CEO stated, “The Validus acquisition captures a top-tier oil resource with a meaningful runway of highly economic inventory that is complementary to our existing footprint in the Eagle Ford. This accretive transaction also enhances our financially-driven strategy that is designed to deliver per-share financial growth and accelerate the return of capital to our shareholders.” TRANSACTION HIGHLIGHTSImmediately...

Continue reading

Eagle Pharmaceuticals Reports Second Quarter 2022 Results

•   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share •   Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily reflecting product sales of vasopressin and PEMFEXY® •   First half 2022 adjusted non-GAAP earnings per diluted share1 more than doubled to $5.60 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company’s history •   First half 2022 revenue of $190 million exceeds full year 2021 revenue of $171.5 million •   First half 2022 net sales of vasopressin and PEMFEXY combined totaled $99.4 million •   Cash and net receivables totaled $122.5 million at June 30, 2022, after the acquisition of Acacia Pharma Group plc (“Acacia”) •   Completed acquisition of Acacia,...

Continue reading

Endeavour Silver Announces Q2 2022 Financial Results; Raises 2022 Production Guidance

VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) is pleased to announce its financial and operating results for the three and six months ended June 30, 2022. As a result of the Company’s strong operating performance, Management has raised its 2022 production guidance. All dollar amounts are in US dollars (US$).   “We have continued to outperform our mine plans, by delivering an exceptional Q2 with production 15% above plan, stated Dan Dickson, CEO of Endeavour Silver. “This has prompted management to raise our production outlook for 2022 to 7.6 – 8.0 million silver equivalent ounces. The additional production has allowed us to maintain our cost guidance on per ounce metrics, but industry-wide inflation continues to be a challenge. We are seeing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.